Boston Scientific exercised its option to acquire the remaining 73% of Farapulse. The stake is worth $295 million plus an additional payment of up to $92 million if certain clinical and regulatory milestones are reached. Boston Scientific now owns 27% of Farapulse. The transaction is expected to close in Q3 2021.
Boston Scientific exercised its option to acquire the remaining 73% of Farapulse. The stake is worth $295 million plus an additional payment of up to $92 million if certain clinical and regulatory milestones are reached. Boston Scientific now owns 27% of Farapulse. The transaction is expected to close in Q3 2021. 
English (US) 